Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808478 | 0.82 | EPHX2 (0.66) | EPHX2HSD11B1 | |
| SCHEMBL19807164 | 0.79 | CYP17A1 (0.49) | CYP1A2CYP3A4CYP2C9CYP17A1CYP19A1 | |
| SCHEMBL9334741 | 0.77 | TSHR (0.61) | CYP1A2CYP3A4CYP2C9CYP17A1CYP19A1 | |
| SCHEMBL3363335 | 0.77 | SMN1; SMN2 (0.65) | CYP1A2CYP17A1CYP19A1HSD11B1P2RX7 | |
| SCHEMBL12726019 | 0.75 | SIGMAR1 (0.68) | CYP1A2CYP3A4CYP2C9SIGMAR1EPHX2 | |
| SCHEMBL20724728 | 0.75 | EPHX2 (0.60) | EPHX2 | |
| SCHEMBL23972940 | 0.74 | EPHX2 (0.68) | CYP1A2CYP3A4CYP2C9SIGMAR1EPHX2 | |
| SCHEMBL6800466 | 0.74 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2C9SIGMAR1EPHX2 | |
| SCHEMBL3455150 | 0.74 | EPHX2 (0.61) | SIGMAR1EPHX2HSD11B1 | |
| SCHEMBL2568441 | 0.72 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2C9SIGMAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
| WO-2016131380-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO.,LTD. (CN) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | CYP1A2 116/4885CYP3A4 72/4885CYP2C9 49/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | CYP1A2 116/4885CYP3A4 72/4885CYP2C9 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.